Anthropic to develop its own pharmaceuticals
Anthropic plans to develop its own drugs rather than just providing AI tools for pharmaceutical companies, according to a report from STAT News.
This move follows the launch of Claude Science, a workspace built for life science researchers. Anthropic is now shifting from a tool provider to an active participant in drug development.
Specific program details and therapeutic focus areas have not yet been disclosed.
Up next
Claude Desktop turned into a C2 agent via configuration poisoning
Pentera Labs injected a base64 prompt into Claude Desktop settings, which synced to all victim devices. Claude then acted as a persistent C2 channel, running bash commands sent by the attacker. Anthropic maintains this is not a vulnerability, as settings and MCP connectors are designed to execute code.
Related stories
- Bloomberg: Anthropic IPO buyers eye as low as $1.1 trillion
- Investors doubt even the lowered $1.5T Anthropic valuation
- Claude Code head of product Cat Wu leaves Anthropic
- Anthropic’s IPO site is live; road show could start Nov. 9
- Anthropic’s Q3 revenue hit $17B as growth slowed to 47%
- Anthropic buys Mithril, a one-person biotech run on Claude
Comments
No comments yet. Be the first.
Join the conversation
Sign in to leave a comment. It appears after moderation.